Lab
Avera Mckennan
Avera Mckennan was paid $2.04M by Medicaid between Jan 2018 and Dec 2024, across 101 billing codes. Its largest line is 87591, Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe — 12% of everything it billed.
33Billing provider infoAVERA MCKENNAN
SIOUX FALLS, SD 57105
SIOUX FALLS, SD 57105
33aNPI1891718136assigned 07/26/2006
33bProvider typeClinical Medical Laboratory
28Total paid$2.04M
24GClaims110,968
24DCodes billed101
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in South Dakota
Rank by total paid#2 of 12
Median peer was paid$312K
This provider vs. median6.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FLICEK, DAVID controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,363 | $221K | |
| 2019 | 10,282 | $189K | |
| 2020 | 7,033 | $150K | |
| 2021 | 12,008 | $224K | |
| 2022 | 22,077 | $411K | |
| 2023 | 22,848 | $373K | |
| 2024incomplete | 24,357 | $472K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 12% | 7,656 | 6,802 | $237K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 11% | 7,574 | 6,730 | $234K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.6% | 2,361 | 2,228 | $175K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 7.4% | 1,287 | 1,189 | $152K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 4.7% | 3,135 | 2,902 | $96K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.5% | 2,973 | 2,752 | $72K |
| 0240U | 3.4% | 666 | 623 | $69K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.9% | 3,134 | 2,761 | $60K |
| 86780 | 2.5% | 4,659 | 4,241 | $51K | |
| 87660 | 2.4% | 2,637 | 2,365 | $49K | |
| 87510 | 2.4% | 2,633 | 2,361 | $48K | |
| 87480 | 2.4% | 2,628 | 2,358 | $48K |
89 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.2% | 6,176 | $46K |
| 86481 | 1.8% | 458 | $37K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.8% | 2,415 | $37K |
| 87077 | 1.4% | 3,387 | $29K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 4,392 | $29K |
| 86803 | 1.4% | 2,389 | $29K | |
| 86762 | 1.3% | 2,183 | $26K | |
| 87340 | 1.2% | 2,970 | $25K | |
| 87186 | 1.2% | 2,707 | $24K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 497 | $22K |
| 80074 | 1.1% | 597 | $22K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,107 | $20K |
| 80081 | <1% | 294 | $19K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 263 | $18K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,020 | $18K |
| 83655 | <1% | 1,573 | $18K | |
| 87081 | <1% | 2,779 | $16K | |
| 82784 | <1% | 1,383 | $16K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 48 | $15K |
| 87070 | <1% | 1,763 | $15K | |
| 82607 | <1% | 1,139 | $14K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 932 | $14K |
| 86850 | <1% | 1,619 | $13K | |
| 82728 | <1% | 950 | $11K | |
| 84439 | <1% | 1,472 | $11K | |
| 87634 | <1% | 155 | $9K | |
| 83001 | <1% | 563 | $9K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 108 | $8K |
| 86376 | <1% | 638 | $8K | |
| 84481 | <1% | 540 | $8K | |
| 86364 | <1% | 728 | $7K | |
| 83516 | <1% | 321 | $7K | |
| 86039 | <1% | 728 | $7K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 501 | $7K |
| 81479 | Unlisted molecular pathology procedure | <1% | 84 | $7K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 151 | $7K |
| 80061 | Lipid panel | <1% | 599 | $7K |
| 84146 | <1% | 365 | $6K | |
| 86592 | <1% | 1,595 | $6K | |
| 82670 | <1% | 244 | $6K | |
| 86787 | <1% | 501 | $6K | |
| 83550 | <1% | 726 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 613 | $5K |
| 84403 | <1% | 234 | $5K | |
| 83540 | <1% | 910 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 265 | $5K |
| 87522 | Neg quan hep c or qual rna | <1% | 129 | $4K |
| 86480 | <1% | 72 | $4K | |
| 86900 | <1% | 1,593 | $4K | |
| 86317 | <1% | 284 | $4K | |
| 86258 | <1% | 375 | $4K | |
| 86901 | <1% | 1,564 | $4K | |
| 81001 | <1% | 1,261 | $3K | |
| 83525 | <1% | 236 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 85 | $3K |
| 85004 | <1% | 506 | $3K | |
| 82570 | <1% | 486 | $2K | |
| 82746 | <1% | 186 | $2K | |
| 83970 | <1% | 71 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 51 | $2K |
| 87046 | <1% | 132 | $2K | |
| 80055 | <1% | 52 | $2K | |
| 83002 | <1% | 94 | $2K | |
| 87338 | <1% | 117 | $1K | |
| 86140 | <1% | 224 | $1K | |
| 85048 | <1% | 522 | $1K | |
| 86431 | <1% | 218 | $1K | |
| 87045 | <1% | 116 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 139 | $981.85 |
| 85027 | <1% | 118 | $964.51 | |
| 84156 | <1% | 254 | $884.52 | |
| 87209 | <1% | 46 | $781.35 | |
| 80177 | <1% | 68 | $764.77 | |
| 86704 | <1% | 63 | $702.99 | |
| 84144 | <1% | 33 | $656.68 | |
| 87147 | <1% | 139 | $612.37 | |
| 87075 | <1% | 56 | $435.09 | |
| 86665 | <1% | 12 | $394.35 | |
| 87177 | <1% | 46 | $386.66 | |
| 84681 | <1% | 13 | $270.05 | |
| 80197 | <1% | 22 | $262.93 | |
| 87807 | <1% | 14 | $246.40 | |
| 82105 | <1% | 14 | $240.39 | |
| 80164 | <1% | 13 | $199.61 | |
| 87329 | <1% | 14 | $166.43 | |
| 85652 | <1% | 45 | $135.43 | |
| 84550 | <1% | 18 | $118.08 | |
| 85045 | <1% | 26 | $88.44 | |
| 81418 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFLICEK, DAVID (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Avera Mckennan | Sioux Falls, SD | $9.09M |
| Avera Mckennan | Sioux Falls, SD | $2.56M |
| Avera Mckennan | Sioux Falls, SD | $2.34M |
| Avera Mckennan | Sioux Falls, SD | $1.86M |
| Avera Mckennan | Sioux Falls, SD | $1.80M |
| Avera Mckennan | Sioux Falls, SD | $1.44M |
| Avera Mckennan | Sioux Falls, SD | $1.38M |
| Avera Mckennan | Sioux Falls, SD | $857K |
| Avera Mckennan | Sioux Falls, SD | $507K |
| Avera Mckennan | Sioux Falls, SD | $445K |
| Avera Mckennan | Gregory, SD | $397K |
| Avera Mckennan | Sioux Falls, SD | $307K |
| Avera Mckennan | Sioux Falls, SD | $280K |
| Avera Mckennan | Sioux Falls, SD | $246K |
| Avera Mckennan | Worthington, MN | $240K |
| Avera Mckennan | Windom, MN | $176K |
| Avera Mckennan | Sioux Falls, SD | $104K |
| Avera Mckennan | Sioux Falls, SD | $95K |
| Avera Mckennan | Sioux Falls, SD | $93K |
| Avera Mckennan | Sioux Falls, SD | $62K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.